MaxCyte, Inc. (MXCT)
Automate Your Wheel Strategy on MXCT
With Tiblio's Option Bot, you can configure your own wheel strategy including MXCT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MXCT
- Rev/Share 0.3556
- Book/Share 1.8821
- PB 1.222
- Debt/Equity 0.0944
- CurrentRatio 12.2318
- ROIC -0.2294
- MktCap 244532630.0
- FreeCF/Share -0.3111
- PFCF -7.4197
- PE -5.8312
- Debt/Assets 0.0818
- DivYield 0
- ROE -0.1989
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.09 per share a year ago.
Read More
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
MaxCyte (MXCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
MaxCyte (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Positive
MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.
Read More
About MaxCyte, Inc. (MXCT)
- IPO Date 2021-07-30
- Website https://maxcyte.com
- Industry Medical - Devices
- CEO Maher Masoud
- Employees 114